Sun Pharma oral semaglutide wins CDSCO approval with an Assam plant and a Chinese ingredient

Sun Pharmaceutical Industries has won approval from India's Central Drugs Standard Control Organisation (CDSCO) to make and sell a generic semaglutide tablet for type 2 diabetes. Sun Pharma oral semaglutide would join pills already launched by Torrent Pharma and Dr Reddy's, according to a Medical Dialogues report that cites ETPharma. The tablets are to be made in Assam from an active ingredient bought in China. The reports give no launch date, brand name or price, and a separate patent still covers the oral formulation of Novo Nordisk's original pill.

What the CDSCO approval covers

The permission lets Sun manufacture and market a once daily semaglutide tablet that the report calls therapeutically equivalent to Rybelsus, the oral form of the GLP 1 drug sold by Novo Nordisk. It covers three tablet strengths, the same three for which Dr Reddy's has published prices, and the stated use is type 2 diabetes, not weight loss. CDSCO is the national drug regulator, and its clearance is the step a company needs before it can sell a generic medicine across India. The reports do not say on what date the approval was signed, and no CDSCO document was quoted. Medical Dialogues reported the approval on 1 November 2026 and credited ETPharma for the details on the plant and the ingredient behind Sun Pharma oral semaglutide.

Semaglutide is a peptide medicine that copies the action of GLP 1, one of the gut hormones that help the body control blood sugar. Drugs of this incretin type were first used for diabetes, and their use has since widened. The molecule is now also used to treat obesity and, in selected adults, to lower the risk of major heart and blood vessel events. Most semaglutide is given as an injection, which makes a tablet a different product to develop, test and make at scale. For Indian patients with type 2 diabetes, a third generic pill would add another choice beside the injectable copies that reached the market after the main patent lapsed earlier this year. Whether it also adds price pressure depends on figures Sun has not yet shared.

A Kamrup plant and a Hangzhou ingredient

According to ETPharma, as cited by Medical Dialogues, Sun will make the tablets at its own facility in Kamrup, a district of Assam in the northeast of the country. The formulation is described as being of recombinant DNA origin, which means the peptide chain is produced by engineered living cells rather than assembled purely by chemistry. That production route shapes the kind of plant a maker needs, as our explainer on yeast and resin peptide production sets out. The active ingredient itself will not be made in India. The report says Sun will buy it from Zhongmeihuadong Pharmaceutical, a company based in Hangzhou, China, and it gives no volume, contract length or price for that supply arrangement.

A tablet finished in Assam from a peptide ingredient made in Hangzhou ties the launch to a supply chain that crosses a national border.

This split between Indian finishing and Chinese ingredient supply is the most concrete new fact in the reports. A tablet finished in Assam from a peptide ingredient made in Hangzhou ties the launch to a supply chain that crosses a national border. That is not a sign of any problem, and no quality concern about the Hangzhou supplier has been reported. It does mean the speed and steadiness of Sun's rollout will depend partly on a factory that Sun does not own. Peptide supply has been a weak point for at least one other Indian generic maker this year, and our desk has followed one case in which a scaled up ingredient batch halted pen shipments. The reports do not say whether Sun plans a second supplier or its own ingredient line later.

The oral semaglutide patent still stands

The main patent on semaglutide expired in India in March this year, the report says, which opened the door to cheaper injectable copies. Our semaglutide patent expiry map tracks how that clock has run in other markets. The tablet is a different case. A separate patent continues to protect the oral formulation in India, so a company making a generic pill has to show that its own recipe falls outside that claim or face a possible dispute. The reports describe this oral semaglutide patent only in general terms. They do not give its number, its expiry date or the exact features it covers, so readers should treat any claim about when the tablet market fully opens with caution.

Torrent Pharma was the first company to launch a generic oral semaglutide, under the brand names Semalix and Sembolic. It did so after the Delhi High Court held that its formulation did not infringe the Novo Nordisk patent, according to the report. That ruling applied to Torrent's own product, not to the tablet class as a whole. The reports say nothing about how Sun has dealt with the same patent, whether through a court finding, a licence or a design it believes is outside the claims. In India, drug approval and patent disputes run on separate tracks: the regulator rules on quality and equivalence, while courts decide infringement. A CDSCO approval therefore does not by itself settle whether a product can be sold without a legal challenge.

Generic Rybelsus rivals and the open questions

The market Sun is entering already has two generic Rybelsus versions. Torrent moved first, and Dr Reddy's, which is headquartered in Hyderabad, followed with its brand Obeda. ETPharma reports that Obeda is priced at Rs 99, Rs 135 and Rs 225 per tablet for the lowest, middle and highest strengths. On our arithmetic, 30 tablets at those prices would cost Rs 2,970, Rs 4,050 and Rs 6,750. No price for the Torrent tablets was given in the reports, and none is reported for Sun. These figures are the main public guide to semaglutide prices in India for the pill form, while injectable copies such as the Eris Sundae brand compete on a different format.

Several things are still unknown. The reports give no brand name, launch date or price for Sun Pharma oral semaglutide, and no sales target or forecast from the company. Novo Nordisk's response to a third generic tablet has not been reported, and neither has any new court filing. The regulator is also weighing Novo's own next step in the class. Medical Dialogues separately reported that a CDSCO expert panel has asked Novo Nordisk for more data on Wegovy tablets for weight management. For now, the confirmed facts are narrow: an approval, three strengths, a plant in Kamrup and an ingredient supplier in Hangzhou. The next signals to watch are a launch announcement from Sun and any legal move by Novo.

Conclusion

Sun Pharma oral semaglutide has cleared India's drug regulator, and it would become the third reported generic tablet in a market where Torrent and Dr Reddy's already sell pills. The approval rests on a Kamrup plant and a Hangzhou ingredient supplier, as ETPharma reported. Price, brand, timing and the patent position remain unreported. Until Sun names a launch date and Novo Nordisk shows its hand, the approval is a licence to sell rather than a product on pharmacy shelves.